Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
7.7M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
49.8K
-
Shares change
-
+49.8K
-
Total reported value, excl. options
-
$91.7K
-
Value change
-
+$91.6K
-
Number of buys
-
11
-
Price
-
$1.84
Significant Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q2 2025
12 filings reported holding ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share as of Q2 2025.
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8K shares
of 7.7M outstanding shares and own 0.65% of the company stock.
Largest 10 shareholders include GEODE CAPITAL MANAGEMENT, LLC (20.1K shares), Corient Private Wealth LLC (17.5K shares), Sippican Capital Advisors (10K shares), BlackRock, Inc. (820 shares), MORGAN STANLEY (554 shares), UBS Group AG (548 shares), ASSETMARK, INC (133 shares), EverSource Wealth Advisors, LLC (116 shares), BANK OF AMERICA CORP /DE/ (21 shares), and BNP PARIBAS FINANCIAL MARKETS (10 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.